An Open-label Pilot Multicenter Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
ADC Therapeutics Sarl
Start Date
August 12, 2020
End Date
August 14, 2025
Administered By
Duke Cancer Institute
Awarded By
ADC Therapeutics Sarl
Start Date
August 12, 2020
End Date
August 14, 2025